#United States #Palatin Technologies #Princeton #PTN #Nasdaq Capital Market

Palatin Technologies Set to Begin Trading on Nasdaq

Palatin Technologies, Inc., a biopharmaceutical company renowned for its efforts in discovering innovative therapeutics, is poised to mark a significant transition by beginning trading on the Nasdaq Capital Market on May 29, 2026. This strategic shift follows recent approvals and is expected to enhance the visibility and liquidity of its common stock.

Transition to Nasdaq

Based in Princeton, New Jersey, Palatin Technologies has received approval to transfer its listing from the NYSE American, under which it has been trading under the symbol "PTN". The company will continue to trade on NYSE American until the market closes on May 28, 2026. This move to Nasdaq is aimed primarily at improving trading conditions and increasing interest from institutional investors, according to Carl Spana, the company’s President and CEO. He emphasized that joining Nasdaq aligns Palatin with a community of leading biotechnology companies, allowing it to expand its presence in the dynamic biotech field.

Focused on Innovative Therapies

Palatin Technologies specializes in developing novel products that target the melanocortin receptor system. The company is actively advancing obesity treatment programs, particularly focusing on rare disorders associated with the MC4R pathway. These include hypothalamic obesity, Prader-Willi syndrome, and Bardet-Biedl syndrome. The emphasis on improving tolerability and the development of long-term usage therapies highlights Palatin's commitment to addressing significant unmet medical needs.

Upcoming Developments

The company's once-weekly injectable MC4R selective peptide agonist is on schedule for an Investigational New Drug (IND) submission in the fourth quarter of 2026. In addition, Palatin is making strides with its oral MC4R selective agonist program, with plans to submit for IND approval for a next-generation oral candidate in the first half of 2027. These development initiatives are part of a broader strategy to create best-in-class MC4R candidates that not only enhance potency but also mitigate off-target effects that can lead to issues such as hyperpigmentation.

Stockholder Guidance

For existing stockholders, no further action is necessary regarding the transfer of the company’s listing. This seamless transition is designed to minimize disruption while enhancing the company’s market engagement.

Looking Ahead

As a forward-looking biopharmaceutical firm, Palatin Technologies is driven by a commitment to innovate and collaborate with industry leaders to maximize the commercial potential of its products. With an evolving portfolio aimed at high-impact medical therapies, the shift to Nasdaq signifies a new chapter for Palatin, paving the way for potential growth and success in the competitive biopharma landscape.

For more detailed information about Palatin Technologies and their innovative approaches to treatment, interested parties are encouraged to visit their official website and follow them on social media platforms.

In summary, Palatin’s move to Nasdaq represents not only a strategic business decision but also a significant milestone in its mission to revolutionize treatment options for patients with critical health challenges. The support of institutional investors and the opportunity for enhanced visibility in the market are set to bolster Palatin's operational capabilities as it embarks on this exciting new phase.